The pandemic puppies are coming of age. Parks are full of toddler cockapoos and labradors, tangled leads in the grip of well-remunerated dog walkers. I can only lament the lack of a listed doggy day-care provider to invest in.
But more pets — three million households have bought one since the start of the pandemic— mean more vets’ bills, and more vets’ bills spark interest in Dechra Pharmaceuticals.
The company, whose products include Amoxicillin dog antibiotics and best-selling Vetoryl, used to treat dogs with hormonal problems, has already received its pandemic bonus: it nuzzled its way into the FTSE 100 in December. Since then, however, the shares have lost almost 20 per cent of their value as part of a vet sector sell-off and
